Botanical species · safety record

Ptelea trifoliata

The EFSA Compendium of Botanicals holds 11 constituent measurements for Ptelea trifoliata. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Ptelea trifoliata L.

11Constituent measurements

0Safety records

7Cited sources

14Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 14 licensed products naming Ptelea trifoliata as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Source material stated

Bark

What the records describe

Constituents measured

Plant parts

Preparations

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Furoquinoline alkaloids	Aerial part of plants	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	Resolve DOI
Kokusaginine	Roots and other underground parts	Solvent extraction	0.015 Percent	Chromatographic tests	Resolve DOI
Alkaloids	Leaves	Solvent extraction	—	Element spectroscopy	No resolvable identifier
Furoquinoline alkaloids	Leaves	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	No resolvable identifier
Isopimpinellin	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Marmesin	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Myrcene	Bark	Essential oil	1.9 Percent	GC-MS	No resolvable identifier
Myrcene	Leaves	Essential oil	≤ 18.7 Percent	GC-MS	No resolvable identifier
Myrcene	Leaves	Essential oil	≥ 8.7 Percent	GC-MS	No resolvable identifier
Phellopterin	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier
Quinoline alkaloids	Leaves	Solvent extraction	—	Nuclear Magnetic Resonance (NMR)	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

MULVEY, RK., ZALEWSKI, CJ. KOKUSAGININE - PLANT SOURCES AND ITS ISOLATION FROM PTELEA TRIFOLIATA ROOT BARK . Economic botany, 1969, vol. 23, no. 1, p. 75-&. DOI
PETITPALY, G., MONTAGU, M., MERIENNE, C., AMBROSE, JD., RIDEAU, M., VIEL, C., CHENIEUX, JC. NEW ALKALOIDS FROM PTELEA-TRIFOLIATA. Planta medica, 1989, no. 2, p. 209-210.
Steinberg, Kelly Marie., Satyal, Prabodh., Setzer, William N. Bark Essential Oils of Zanthoxylum clava-herculis and Ptelea trifoliata: Enantiomeric Distribution of Monoterpenoids . Natural product communications, 2017, vol. 12, no. 6, p. 961-963.
Takaku, Sayaka., Setzer, William N. Chemical composition of the leaf essential oil of Ptelea trifoliata. Journal of essential oil bearing plants, 2007, vol. 10, no. 2, p. 104-108.
RIDEAU, M., VERCHERE, C., HIBON, P., CHENIEUX, JC., MAUPAS, P., VIEL, C. DIHYDROFUROQUINOLINE ALKALOIDS FROM RUTACEAE - ISOLATION, STRUCTURE, BIOLOGICAL PROPERTIES . Phytochemistry, 1979, vol. 18, no. 1, p. 155-159. DOI
Dreyer, David L. Chemotaxonomy of the Rutaceae. V. Coumarins and alkaloids of the genus Ptelea. Phytochemistry (elsevier), 1969, vol. 8, no. 6, p. 1013-20.
Pothier, Jacques., Petit-Paly, Genevieve., Montagu, Monique., Galand, Nicole., Chenieux, Jean Claude., Rideau, Marc., Viel, Claude. Separation of quinolizidine and dihydrofuro 2,3-b quinolinium alkaloids by overpressured layer chromatography (OPLC). Journal of planar chromatography--modern tlc, 1990, vol. 3(July-Aug.), p. 356-8.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature